Factor 1: tolerance
We are dedicated to your health and well-being
Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes (AWARD-11): a randomised, double-blind, placebo-controlled, phase 3 trial
The clinician's prescribing decision is final, payment does not guarantee a prescription, and any decision about whether to start, continue, or stop a GLP-1 treatment should be made in consultation with a qualified licensed healthcare professional
Methods Fifty-six subjects, categorized into renal function groups [normal, mild, moderate, severe, and end-stage renal disease (ESRD)], received a single subcutaneous dose of semaglutide 0.5 mg
You don't blame people who have asthma for having asthma